Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis

Journal of Managed Care Pharmacy

Volumn 20, Issue 7, 2014, Pages 657-667

  Oladapo, Abiola ^a   Barner, Jamie C ^b   Lawson, Kenneth A ^b   Novak, Suzanne ^b   Rascati, Karen L ^b   Richards, Kristin M ^b   Harrison, David J ^c  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; CORTICOTROPIN; CORTISONE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; HYDROCORTISONE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TRAMADOL; TRIAMCINOLONE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ALGORITHM; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICATION COMPLIANCE; RHEUMATOID ARTHRITIS; UNITED STATES; AMBULATORY CARE; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HISPANIC; HOSPITAL PATIENT; PATIENT COMPLIANCE; PRESCRIPTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; TEXAS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TEXAS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; YOUNG ADULT;

EID: 84903210820     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.7.657     Document Type: Article

References (51)

1. Punzi L, Matucci Cerinic M, Cantini F, et al. Treatment patterns of anti- TNF agents in Italy: an observational study. Reumatismo. 2011;63(1):18-28.
2. Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin. 2009;25(6):1365-77.
3. Centers for Disease Control and Prevention. Rheumatoid arthritis. 2011. Available at: http://www.cdc.gov/arthritis/basics/rheumatoid.htm. Accessed May 15, 2014.
4. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30(7):1375-84.
5. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586-93.
6. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594-602.
7. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.
8. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(4):964-75.
9. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804.
10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
11. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063-74.
12. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33(12):2398-408.
13. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(Suppl 2):ii13-16.
14. Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int. 2008;28(6):553-59.
15. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold- Samsøe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol. 2007;36(6):411-17.
16. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148(2):124-34.
17. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30(4):339-53.
18. U.S. Food and Drug Administration. HUMIRA (adalimumab) product approval information. Licensing action (label). Abbott Laboratories. December 2002. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm092762.pdf. Accessed May 15, 2014.
19. U.S. Food and Drug Administration. REMICADE (infliximab) product approval information. Licensing action (label). Centocor Inc. February 2002. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107713.pdf. Accessed May 15, 2014.
20. U.S. Food and Drug Administration. ENBREL (etanercept) product approval information. Licensing action (label). Amgen and Wyeth Pharmaceuticals. June 2003. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088826.pdf. Accessed May 15, 2014.
21. Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40(1):2-14.
22. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-27.
23. Kim S, Servi A, Polinski J, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011;13(1):R32.
24. Curtis JR, Baddley JW, Yang S, et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther. 2011;13(5):R155.
25. Curtis JR, Chastek B, Becker L, et al. Further evaluation of a claimsbased algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data. Arthritis Res Ther. 2013;15(2):404.
26. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27(12):2037-49.
27. Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013;24(3):401-09.
28. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin. 2008;24(8):2229-40.
29. Bonafede MM, Gandra SR, Fox KM, Wilson KL. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ. 2012;15(4):635-43.
30. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient outof- pocket payments matter? Arthritis Rheum. 2008;59(10):1519-26.
31. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45(10 Suppl 2):S66-S76.
32. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Adherence to disease modifying anti-rheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Arthritis Care Res (Hoboken). 2010;62(5):730-34.
33. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9(6 Suppl):S136-S43.
34. Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm. 2010;67(15):1281-87.
35. Huang X, Gu NY, Fox KM, Harrison DJ, Globe D. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin. 2010;26(7):1637-45.
36. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health. 2010;13(6):805-12.
37. Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin. 2012;28(4):569-80.
38. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol. 2009;36(5):907-13.
39. Gu N, Huang X, Fox K, Patel V, Baumgartner S, Chiou C. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits. 2010;2(6):351-59.
40. Fisher MD, Watson C, Fox KM, Chen YW, Gandra SR. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Curr Med Res Opin. 2013;29(5):561-68.
41. Carter CT, Changolkar AK, Scott McKenzie R. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ. 2012;15(2):332-39.
42. Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factorantagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31(4):825-35.
43. The Henry J. Kaiser Family Foundation. Population distribution by race/ethnicity. 2013. Available at: http://kff.org/other/state-indicator/distributionby- raceethnicity/?state=TX. Accessed May 16, 2014.
44. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez- Arboleya L, Navarro-Compán V, Toyos J. Dose escalation of the anti-TNFalpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford). 2007;46(3):529-32.
45. Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol. 2011;29(1):26-34.
46. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1233-38.
47. Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 2008;58(7):1921-30.
48. Blume SW, Fox KM, Joseph G, Chuang CC, Thomas J, Gandra SR. Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting. Adv Ther. 2013;30(5):517-27.
49. Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther. 2009;11(1):R26.
50. van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009;36(10):2164-70.
51. Rassen JA, Doherty M, Huang W, Schneeweiss S. Pharmacoepidemiology toolbox. Brigham and Women's Hospital Department of Medicine. Available at: http://www.drugepi.org/dope-downloads/#Pharmacoepidemiology Toolbox. Accessed May 16, 2014.